|
|
Article: FTC gives nod to Carl Icahn for ImClone stock. (Markets: Life Sciences).(Federal Trade Commission approves stock purchase)(Brief Article)(Statistical Data Included)
- Article from:
- Chemical Market Reporter
- Article date:
- February 25, 2002
- Author:
CopyrightCOPYRIGHT 2002 Schnell Publishing Company, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ANOTHER TWIST in the shaky $2 billion partnership between Bristol-Myers Squibb Company (BMS) and ImClone Systems Inc. occurred last week when the Federal Trade Commission (FTC) gave clearance for financier Carl C. Icahn to purchase $500 million of ImClone stock or roughly 40 percent of the company. The FTC clearance followed the adoption of a shareholder rights program by ImClone.
Earlier this month, Mr. Icahn filed for clearance with the FTC and the Department of Justice to acquire up to $500 million of ImClone's stock. The FTC granted Mr. Icahn early termination of the waiting period under the Hart-Scott-Rodino Act. The full waiting period would have expired on ...
Related newspaper, magazine, and journal articles:
|
|
Article: ImClone Nixes BMS Proposal, Says a New Suitor has ...
BIOWORLD Today;
September 11, 2008 ;
700+ words
... ... special committee, according to ImClone. A BMS spokesman declined to comment ... it "makes more sense" for BMS to buy ImClone, since it is set to lose rights ... sense for parties other than ImClone partners BMS and Merck KGaA, which markets ...
|
|